Niagen Bioscience, Inc. (NAGE) stock
NAGENasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3011% below fair value
$1.94−0.10 (-4.90%)
Close on Nov 18, 2026Market cap $153.50MP/E 16.2Yield –
Niagen Bioscience revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Niagen Bioscience's revenue for the twelve months ending Sep 30, 2026 was $122.29M, down 1.9% year over year. For fiscal 2025 it was $129.42M, up 29.9% from the year before. Over ten years it grew 21.9% a year on average. The highest annual figure on record is $129.42M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $129.42M | +29.9% |
| FY2024 | Dec 31, 2024 | $99.60M | +19.2% |
| FY2023 | Dec 31, 2023 | $83.57M | +16.0% |
| FY2022 | Dec 31, 2022 | $72.05M | +6.8% |
| FY2021 | Dec 31, 2021 | $67.45M | +13.8% |
| FY2020 | Dec 31, 2020 | $59.26M | +28.0% |
| FY2019 | Dec 31, 2019 | $46.29M | +46.7% |
| FY2018 | Dec 31, 2018 | $31.56M | +48.8% |
| FY2017 | Dec 30, 2017 | $21.20M | -2.1% |
| FY2016 | Dec 31, 2016 | $21.66M | +21.1% |
| FY2015 | Jan 2, 2016 | $17.88M | +16.8% |
| FY2014 | Jan 3, 2015 | $15.31M | +50.7% |
| FY2013 | Dec 28, 2013 | $10.16M | -12.5% |
| FY2012 | Dec 29, 2012 | $11.61M | +43.1% |
| FY2011 | Dec 31, 2011 | $8.11M | +7.2% |
| FY2010 | Jan 1, 2011 | $7.57M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $27.19M | -20.0% |
| Q2 FY2026 | Jun 30, 2026 | $29.79M | -4.3% |
| Q1 FY2026 | Mar 31, 2026 | $31.47M | +3.3% |
| Q4 FY2025 | Dec 31, 2025 | $33.84M | +16.2% |
| Q3 FY2025 | Sep 30, 2025 | $33.99M | +32.9% |
| Q2 FY2025 | Jun 30, 2025 | $31.12M | +36.8% |
| Q1 FY2025 | Mar 31, 2025 | $30.48M | +37.6% |
| Q4 FY2024 | Dec 31, 2024 | $29.13M | +37.4% |
| Q3 FY2024 | Sep 30, 2024 | $25.58M | +31.2% |
| Q2 FY2024 | Jun 30, 2024 | $22.74M | +11.9% |
| Q1 FY2024 | Mar 31, 2024 | $22.15M | -1.8% |
| Q4 FY2023 | Dec 31, 2023 | $21.20M | +1.0% |
| Q3 FY2023 | Sep 30, 2023 | $19.50M | +14.3% |
| Q2 FY2023 | Jun 30, 2023 | $20.32M | +21.5% |
| Q1 FY2023 | Mar 31, 2023 | $22.56M | +30.7% |
| Q4 FY2022 | Dec 31, 2022 | $21.00M | +18.2% |
| Q3 FY2022 | Sep 30, 2022 | $17.06M | -1.4% |
| Q2 FY2022 | Jun 30, 2022 | $16.73M | -5.5% |
| Q1 FY2022 | Mar 31, 2022 | $17.26M | +17.5% |
| Q4 FY2021 | Dec 31, 2021 | $17.76M | +15.0% |
| Q3 FY2021 | Sep 30, 2021 | $17.31M | +22.1% |
| Q2 FY2021 | Jun 30, 2021 | $17.70M | +15.8% |
| Q1 FY2021 | Mar 31, 2021 | $14.68M | +2.4% |
| Q4 FY2020 | Dec 31, 2020 | $15.45M | +18.0% |
| Q3 FY2020 | Sep 30, 2020 | $14.18M | +17.6% |
| Q2 FY2020 | Jun 30, 2020 | $15.29M | +37.7% |
| Q1 FY2020 | Mar 31, 2020 | $14.35M | +42.8% |
| Q4 FY2019 | Dec 31, 2019 | $13.09M | +44.4% |
| Q3 FY2019 | Sep 30, 2019 | $12.05M | +48.4% |
| Q2 FY2019 | Jun 30, 2019 | $11.10M | +42.3% |
| Q1 FY2019 | Mar 31, 2019 | $10.05M | +53.0% |
| Q4 FY2018 | Dec 31, 2018 | $9.07M | +20.4% |
| Q3 FY2018 | Sep 30, 2018 | $8.12M | +33.5% |
| Q2 FY2018 | Jun 30, 2018 | $7.80M | +75.2% |
| Q1 FY2018 | Mar 31, 2018 | $6.57M | +66.8% |
| Q4 FY2017 | Dec 30, 2017 | $7.53M | – |
| Q3 FY2017 | Sep 30, 2017 | $6.08M | – |
| Q4 FY2016 | Dec 31, 2016 | $4.45M | – |
| Q3 FY2016 | Oct 1, 2016 | $3.94M | – |
See a number that looks wrong?